Close Menu

cell-free DNA

The firms will use Resolution's ctDx liquid biopsy technology to find non-small cell lung cancer patients who may benefit from Mirati's KRAS G12C inhibitor therapy.

Ravgen has alleged that several leading NGS-based non-invasive prenatal testing and oncology assays infringe two patents held by the firm.

CareDx first sued Natera in March 2019 for infringing two of its patents, then amended the suit a year later to add a third patent.

The firm also discussed recent studies comparing its UltraSeek lung cancer assay with more established liquid biopsy tests to detect drug-resistant mutations.

The company's AlloSure Kidney test received coverage, along with its AlloSure Heart test when used with the firm's AlloMap test.

At the ASHG 2020 virtual meeting, researchers presented data showing they could use the method to enrich for placental DNA in maternal plasma samples.

The firm's platform, dubbed HNKlear, uses methylation-specific PCR to detect microRNA biomarkers in a patient's blood sample following frontline cancer treatment.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The Swiss-American bioinformatics company touts its networks of multimodal data and numerous partnerships as it looks to support "data-driven medicine."

The literature shows high specificity and sensitivity for cfDNA testing in twin pregnancies. It could also be a viable screening option for triplet pregnancies.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.